Please use this identifier to cite or link to this item:
http://ir.mu.ac.ke:8080/jspui/handle/123456789/6264| Title: | Dolutegravir or Darunavir in combination with Zidovudine or Tenofovir to treat HIV |
| Authors: | Siika, Abraham |
| Keywords: | HIV |
| Issue Date: | 2021 |
| Publisher: | The New England Journal of Medicine |
| Abstract: | The World Health Organization recommends dolutegravir with two nucleoside reverse-transcriptase inhibitors (NRTIs) for second-line treatment of human immunodeficiency virus type 1 (HIV-1) infection. Evidence is limited for the efficacy of this regimen when NRTIs are predicted to lack activity because of drug resistance, as well as for the recommended switch of an NRTI from tenofovir to zidovudine |
| URI: | https://www.nejm.org/doi/full/10.1056/NEJMoa2101609 http://ir.mu.ac.ke:8080/jspui/handle/123456789/6264 |
| Appears in Collections: | School of Medicine |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| nejmoa2101609.pdf | 666.63 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.